Pre-made Coprelotamab benchmark antibody ( Whole mAb, anti-ERBB2/HER2 therapeutic antibody, Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-119

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-119 Category Tag

Product Details

Pre-Made Coprelotamab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Coprelotamab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody

INN Name

Coprelotamab

Target

ERBB2

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Active

100% SI Structure

1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD

99% SI Structure

1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC

95-98% SI Structure

5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB

Year Proposed

2020

Companies

Genor Biopharma

Conditions Approved

NA

Conditions Active

Cancers

Conditions Discontinued

NA

Development Tech

Coprelotamab is a biosimilar of Trastuzumab and Timigutuzumab with an identical Variable region. Cinrebafusp have identical V domain.

Previous Name

NA

Gm Offical Target Name

ERBB2/HER2

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide